TY - JOUR
T1 - Validation and comparison of contemporary prognostic models in primary myelofibrosis
T2 - Analysis based on 334 patients from a single institution
AU - Tefferi, Ayalew
AU - Huang, Jocelin
AU - Schwager, Susan
AU - Li, Chin Yang
AU - Wu, Wenting
AU - Pardanani, Animesh
AU - Mesa, Ruben A.
PY - 2007/5/15
Y1 - 2007/5/15
N2 - BACKGROUND. Survival in primary myelofibrosis (PMF) is predicted by several prognostic scoring systems (PSSs); the most widely recognized is that of Dupriez. Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups. METHODS. The Mayo Clinic PMF database was queried to identify a consecutive series of patients in whom pretreatment bone marrow and complete blood count (CBC), obtained within 6 months of diagnosis, were available for review. RESULTS. Among 334 study patients (median age, 57 years), median survival was 70 months. Multivariable analysis of all 6 adverse prognostic factors utilized in the aforementioned PSSs (ie, hemoglobin <10 g/dL, leukocyte count <4 or >30 × 109/L, constitutional symptoms, circulating blasts ≥1%, platelet count <100 × 10 9/L, absolute monocyte count ≥1 × 109/L) identified all but platelet count as being significant. The Mayo PSS, which is based on the 4 CBC-derived parameters (ie, hemoglobin, platelet, leukocyte, and monocyte counts), displayed a better hazard ratio profile compared with the other 2 PSSs in identifying long-lived patients as well as delineating intermediate-risk disease category. The latter effect was even more pronounced in patients younger than age 60 years. CONCLUSIONS. The Mayo PSS for survival in PMF is an objective CBC-derived prognostic model that might be superior in its performance over that of either the Dupriez and Cervantes PSSs.
AB - BACKGROUND. Survival in primary myelofibrosis (PMF) is predicted by several prognostic scoring systems (PSSs); the most widely recognized is that of Dupriez. Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups. METHODS. The Mayo Clinic PMF database was queried to identify a consecutive series of patients in whom pretreatment bone marrow and complete blood count (CBC), obtained within 6 months of diagnosis, were available for review. RESULTS. Among 334 study patients (median age, 57 years), median survival was 70 months. Multivariable analysis of all 6 adverse prognostic factors utilized in the aforementioned PSSs (ie, hemoglobin <10 g/dL, leukocyte count <4 or >30 × 109/L, constitutional symptoms, circulating blasts ≥1%, platelet count <100 × 10 9/L, absolute monocyte count ≥1 × 109/L) identified all but platelet count as being significant. The Mayo PSS, which is based on the 4 CBC-derived parameters (ie, hemoglobin, platelet, leukocyte, and monocyte counts), displayed a better hazard ratio profile compared with the other 2 PSSs in identifying long-lived patients as well as delineating intermediate-risk disease category. The latter effect was even more pronounced in patients younger than age 60 years. CONCLUSIONS. The Mayo PSS for survival in PMF is an objective CBC-derived prognostic model that might be superior in its performance over that of either the Dupriez and Cervantes PSSs.
KW - Primary myelofibrosis
KW - Prognostic scoring systems
UR - http://www.scopus.com/inward/record.url?scp=34248340834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248340834&partnerID=8YFLogxK
U2 - 10.1002/cncr.22630
DO - 10.1002/cncr.22630
M3 - Article
C2 - 17407134
AN - SCOPUS:34248340834
SN - 0008-543X
VL - 109
SP - 2083
EP - 2088
JO - Cancer
JF - Cancer
IS - 10
ER -